These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 7579732)

  • 1. Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells.
    Schultz RM; Andis SL; Shackelford KA; Gates SB; Ratnam M; Mendelsohn LG; Shih C; Grindey GB
    Oncol Res; 1995; 7(2):97-102. PubMed ID: 7579732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
    Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems.
    Westerhof GR; Jansen G; van Emmerik N; Kathmann I; Rijksen G; Jackman AL; Schornagel JH
    Cancer Res; 1991 Oct; 51(20):5507-13. PubMed ID: 1655252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
    Zhao R; Gao F; Babani S; Goldman ID
    Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance.
    Jansen G; Westerhof GR; Kathmann I; Rademaker BC; Rijksen G; Schornagel JH
    Cancer Res; 1989 May; 49(9):2455-9. PubMed ID: 2706633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.
    Sen S; Erba E; D'Incalci M; Bottero F; Canevari S; Tomassetti A
    Br J Cancer; 1996 Feb; 73(4):525-30. PubMed ID: 8595169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
    Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate.
    Pinard MF; Jolivet J; Ratnam M; Kathmann I; Molthoff C; Westerhof R; Schornagel JH; Jansen G
    Cancer Chemother Pharmacol; 1996; 38(3):281-8. PubMed ID: 8646804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds.
    Jansen G; Westerhof GR; Kathmann I; Rijksen G; Schornagel JH
    Cancer Chemother Pharmacol; 1991; 28(2):115-7. PubMed ID: 2060081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
    Erba E; Sen S; Sessa C; Vikhanskaya FL; D'Incalci M
    Br J Cancer; 1994 Feb; 69(2):205-11. PubMed ID: 8297715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
    Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells.
    Henderson GB; Strauss BP
    Cancer Res; 1990 Mar; 50(6):1709-14. PubMed ID: 2306724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of a folate binding protein in L1210 cells grown in low folate medium.
    Jansen G; Kathmann I; Rademaker BC; Braakhuis BJ; Westerhof GR; Rijksen G; Schornagel JH
    Cancer Res; 1989 Apr; 49(8):1959-63. PubMed ID: 2702638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates.
    Chung KN; Saikawa Y; Paik TH; Dixon KH; Mulligan T; Cowan KH; Elwood PC
    J Clin Invest; 1993 Apr; 91(4):1289-94. PubMed ID: 7682567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
    Zhao R; Babani S; Gao F; Liu L; Goldman ID
    Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous changes in various mechanisms that mediate the cell incorporation of folate compounds account for low levels of resistance to methotrexate.
    Cavalcanti F; Calvo N; Grau-Oliete MR; Rivera-Fillat MP
    Cell Biochem Funct; 1992 Mar; 10(1):1-7. PubMed ID: 1533575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
    Wang Y; Zhao R; Goldman ID
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.
    Sierra EE; Goldman ID
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):11-23. PubMed ID: 10598550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration.
    Jansen G; Barr H; Kathmann I; Bunni MA; Priest DG; Noordhuis P; Peters GJ; Assaraf YG
    Mol Pharmacol; 1999 Apr; 55(4):761-9. PubMed ID: 10101035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.